Business
our business as we look to convert our DAAP and MNT customers to a subscription-based model for the data component of our offerings.
OptimizeRx Corp: Revenue grew 18.8% to $109M from $92.13M. Net income turned positive at $5.132M from a $20.11M loss. Free cash flow grew 290.6% to $18.66M from $4.777M. Operating margin expanded 2557 bps to 10.69%. OptimizeRx Corp's principal statistical and annual-change screens add no overriding warning to the reported profit and cash-flow record.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 18.8% to $109M from $92.13MOK
- Profitability — Net income turned positive at $5.132M from a $20.11M lossOK
- Cash flow — Free cash flow grew 290.6% to $18.66M from $4.777MOK
- Margins — Operating margin expanded 2557 bps to 10.69%OK
- Accounting — Controls ineffective; material weaknessWatch
- Insiders — 0 purchases and 3 salesWatch
Where the revenue comes from
Fiscal 2025, as OptimizeRx Corp reports it. History and quarterly detail are in the app.
- Revenue recognized over time$109.2M
- Revenue recognized at a point in time$215K
Leadership changes
From OptimizeRx Corp's own filings, the day they're filed.
- Theresa Greco · Chief Commercial Officer · departureeff. 2026-06-15
- Edward Stelmakh · Chief Financial Officer · appointmenteff. 2025-08-18
- Stephen Silvestro · Chief Executive Officer · appointmenteff. 2025-03-10
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about OptimizeRx Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.